Synthesis of Tiyolat-Bridged Ruthenium Complexes and Investigation of Their Antitumour Properties
Project no. 32313 · Status: Kapanmış · 2024
Summary
<p>In cancer treatment today, cisplatin and other platinum-derived drugs are used as metal-based anticancer drugs. However, due to the widespread side effects and toxic properties of these drugs, ranging from organ loss to hair loss, there is a need for drugs containing other metals. Ruthenium (Ru) is the most suitable candidate to replace platinum due to its intracellular transport mechanism and rich redox chemistry.</p><p>This project investigates N,S,S-coordinated bimetallic Ru(II) aren complexes as potential antitumour agents. It aims to synthesise four different Ru(II) aren complexes, which are not found in the literature, and characterise them using spectroscopic methods. Their cytotoxic properties will be evaluated against three different cancer cell lines (MCF-7, Caco-2, and HePG2) and a healthy cell line (Vero) to assess selectivity. The mechanisms of action will be explored through DNA interaction studies. Furthermore, their stabilities and logP values will be analysed to gain insight into potential drug formulation.</p><p>The original value of the project lies in its potential to discover new ruthenium-based anticancer agents and offers insights into the development of improved treatments. Expected results include the successful synthesis and characterisation of bimetallic complexes, as well as valuable data on their anticancer activities, ultimately advancing both scientific knowledge and potential clinical applications in cancer treatment.</p>